Survival analysis

Intradiem Awarded U.S. Patent for Burnout and Attrition Indicator

Retrieved on: 
Tuesday, May 7, 2024
Mental Health, Technology, Human Resources, Telecommunications, Professional Services, Software, Electronic Design Automation, Data Analytics, Health, Artificial Intelligence, Human, Burnout, LDA, QDA, Patent, Machine learning, Drawing, Organization, Risk, Survival analysis, Pharmaceutical industry

Intradiem, the leading provider of contact center automation solutions for customer service teams, was recently awarded a U.S. patent for its Machine Learning (ML) Burnout and Attrition Indicator solution.

Key Points: 
  • Intradiem, the leading provider of contact center automation solutions for customer service teams, was recently awarded a U.S. patent for its Machine Learning (ML) Burnout and Attrition Indicator solution.
  • Intradiem supports both agent engagement and agent well-being through its revolutionary new solution, which harnesses ML’s predictive power to identify patterns of decreased productivity, stress, and burnout that typically lead to agent attrition.
  • “This patent highlights our ongoing commitment to finding novel ways to solve long-standing problems in our industry," said Intradiem Co-CEO, Matt McConnell.
  • "Early users are already sharing success stories of supervisors being alerted to agent burnout risks and taking actions to head off attrition."

Bitsight Reveals More than 60 Percent of Known Exploited Vulnerabilities Remain Unmitigated Past Deadlines in First-of-its-Kind Analysis of CISA's KEV Catalog

Retrieved on: 
Wednesday, May 1, 2024
Risk, Survival analysis, Sunroom, Member of Congress, Research, Catalog, Knowledge, KEV, TRACE, Risk management, Environment, Organization, Computer security, Prevalence, Cyberspace Solarium Commission, CSO, CISA, Telescope

BOSTON, May 1, 2024 /PRNewswire/ -- Bitsight, the leader in cyber risk management, today released a new report by its TRACE security research team analyzing the Known Exploited Vulnerabilities (KEV) catalog, the Cybersecurity and Infrastructure Security Agency's (CISA) authoritative source of vulnerabilities that have been exploited in the wild.

Key Points: 
  • "Even critical severity vulnerabilities take four and a half months to remediate on average.
  • Key KEV prevalence and remediation findings from the Bitsight TRACE study include:
    Vulnerabilities included in the KEV catalog are highly prevalent and over a third of organizations had at least one in 2023.
  • Despite faster remediation of KEVs versus non-KEVs, more than 60% are remediated after deadlines provided by CISA
    Remediation of KEVs varies based on the severity:
    Known ransomware vulnerabilities are highly prevalent but remediated faster.
  • "The data leaves no doubt: CISA's creation of the KEV catalog has been hugely positive.

Analysis Group Announces Senior-Level Promotions

Retrieved on: 
Thursday, April 4, 2024
HTA, Consumer, Climate change, Bankruptcy, Algorithm, ERISA, Environment, Agriculture, Data analysis, RWE, Materiality, Biostatistics, Research, History, Policy, Epidemiology, Survival analysis, Insurance, Analysis Group, Advertising, Clinical trial, IP, Ground substance, Intellectual property, Telecommunications, Privacy, Marketing, Economics, Consultant

BOSTON, April 4, 2024 /PRNewswire/ -- Analysis Group , one of the largest international economics consulting firms, announces 32 promotions to vice president across nine offices.

Key Points: 
  • BOSTON, April 4, 2024 /PRNewswire/ -- Analysis Group , one of the largest international economics consulting firms, announces 32 promotions to vice president across nine offices.
  • "We are delighted to announce the largest group of consultant promotions to vice president in the history of our organization," said Martha S. Samuelson, CEO and Chairman of Analysis Group.
  • In Boston, Jonathan E. Baker specializes in the application of economic analysis to antitrust and competition, energy and environment, commercial dispute, class certification, and damages litigation matters.
  • Erica VanSant specializes in economic analysis of complex litigation matters in the areas of health care, antitrust, and IP.

WCG Expands New Statistical Consulting Solutions to Address Industry Resource Challenges

Retrieved on: 
Monday, March 4, 2024
Meta-analysis, Adviser, WCG, Survival analysis, ChromeOS, Government, Organization, Health, Partnership, Pharmaceutical industry

PRINCETON, N.J., March 4, 2024 /PRNewswire/ -- WCG, the global leader in providing solutions that measurably improve and accelerate clinical research, announces the expansion of its capabilities with the introduction of Statistical Consulting Solutions.

Key Points: 
  • PRINCETON, N.J., March 4, 2024 /PRNewswire/ -- WCG, the global leader in providing solutions that measurably improve and accelerate clinical research, announces the expansion of its capabilities with the introduction of Statistical Consulting Solutions.
  • Developed to combat some of the pervasive challenges involving resource constraints throughout the clinical research industry, this innovative offering aims to revolutionize how organizations approach statistical analysis and decision-making.
  • WCG's Statistical Consulting Solutions empower biotechnology firms, CROs, pharmaceutical companies, medical device manufacturers, government agencies, and non-profit organizations with comprehensive statistical support across all stages of trial design and regulatory strategy.
  • Whether assisting with early phase studies or providing support for regulatory submissions, WCG's Statistical Consulting Solutions are tailored to meet the diverse needs of the industry.

U.S. FDA Approves Label Update for Kite’s Yescarta® CAR T-Cell Therapy to Include Overall Survival Data

Retrieved on: 
Thursday, December 21, 2023
Oncology, FDA, Health, Hospitals, Pharmaceutical, Biotechnology, ASCT, Survival analysis, Palliative care, Food, Survival, Risk, Arm, HDT, MD, Doctor of Philosophy, B-cell lymphoma, Standard of care, Medicine, Death, European Medicines Agency, Medication package insert, Patient, OS, SOC, Senior, Pharmaceutical industry

The label update is based on results from the ZUMA-7 study which demonstrated a 27.4% reduction in the risk of death with Yescarta versus SOC, a relative 38% improvement in OS.

Key Points: 
  • The label update is based on results from the ZUMA-7 study which demonstrated a 27.4% reduction in the risk of death with Yescarta versus SOC, a relative 38% improvement in OS.
  • The estimated 39-month OS rates were 55.9% in the Yescarta arm and 46% in the SOC arm.
  • “Our ZUMA-7 overall survival analysis proves that when given as second-line therapy, Yescarta is even more effective in improving patient survival than standard of care treatment.
  • *Treatment of curative intent is a line of treatment administered with the goal of achieving a durable complete response/ remission.

Amylyx Pharmaceuticals Announces Publication of Survival Analysis Comparing CENTAUR to Historical Clinical Trial Control

Retrieved on: 
Tuesday, October 10, 2023
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, ACT, Amylyx Pharmaceuticals, ALS, ALS Association, Doctor of Philosophy, Survival analysis, Death, OLE, American Academy, Pro-Act by VTC, Innovation, Health informatics, Propensity score matching, MD, Risk, NCRI, Mass, Mortality, Massachusetts General Hospital, Survival, Hospital, Disease, Translation, CIB, Principal, AMX0035, Database, ITT, Harvard Medical School, Clinical trial, Medication, Common-pool resource, Pharmaceutical industry

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the publication of a post hoc analysis in the peer-reviewed medical journal, Annals of Clinical and Translational Neurology comparing the long term survival of participants in the CENTAUR study versus a historical clinical trial control group.

Key Points: 
  • Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the publication of a post hoc analysis in the peer-reviewed medical journal, Annals of Clinical and Translational Neurology comparing the long term survival of participants in the CENTAUR study versus a historical clinical trial control group.
  • The post hoc survival analysis published today compared CENTAUR clinical trial participants who received AMX0035 against a propensity score-matched, AMX0035-naïve external control cohort from the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database.
  • These results using an external control aligned with prior analysis using statistical models adjusting for placebo-to-active crossover in CENTAUR ( RPSFTM ).
  • Amylyx donated data from the CENTAUR clinical trial to the PRO-ACT database.

Mitsubishi Tanabe Pharma America Announces Post-Hoc Analysis Examining Effect of Early Intervention with RADICAVA® (edaravone) on Survival and Disease Progression Milestones in People with ALS

Retrieved on: 
Thursday, August 17, 2023
Medical Affairs Bureau, PE, Hospital, Edaravone, EE, CI, Survival, PAV, MTPA, Risk, Muscle & Nerve, Tracheotomy, Survival analysis, Death, ALS, Disease, Pharmaceutical industry

JERSEY CITY, N.J., Aug. 17, 2023 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the publication of a post-hoc analysis of the pivotal, Phase 3 study (MCI186-19) reviewing the effect of intravenous (IV) RADICAVA® (edaravone) on survival and additional disease progression milestone events in people with amyotrophic lateral sclerosis (ALS). Results from the analysis, which were published in Muscle & Nerve, suggest that timely and continued treatment with RADICAVA when initiated first was associated with a lower risk of death, tracheostomy, permanent assisted ventilation (PAV) or hospitalization, compared to people with ALS who received placebo first followed by RADICAVA.

Key Points: 
  • During the open-label period, there were two deaths in the EE group and four in the PE group.
  • As these results are from a post-hoc analysis, the results should be interpreted with caution.
  • Lastly, the MCI186-19 study was not powered a priori to analyze the novel composite endpoint of death, tracheostomy, PAV, or hospitalization.
  • "The findings of this post-hoc analysis are encouraging," said Benjamin Rix Brooks, M.D., a longtime leader in ALS research and lead author of the study.

Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023

Retrieved on: 
Wednesday, May 24, 2023
MSD, CREB-binding protein, Apoptosis, Carcinoma, Abstract, Senior, CBP, FR, Pembrolizumab, Cancer, Fallopian tube cancer, Bristol Myers Squibb, Research, Lung cancer, Trial of the century, ASCO, LEAP, Endometrial cancer, American Society of Clinical Oncology, Patient, Physician, Sorafenib, Oncology nursing, Annual general meeting, ADC, Merck, Poster, Merck & Co., FDA, Survival analysis, Ovarian cancer, Society, HCC, Safety, Nivolumab, Pharmaceutical industry, Eisai

Eisai entered into a joint development agreement with BlissBio for BB-1701 with option rights for a strategic collaboration in April 2023.

Key Points: 
  • Eisai entered into a joint development agreement with BlissBio for BB-1701 with option rights for a strategic collaboration in April 2023.
  • A Phase 1/2 clinical study of BB-1701 in the U.S. and China for HER2-expressing solid tumors is currently underway.
  • There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.
  • Eisai and Merck are studying the LENVIMA plus KEYTRUDA combination through the LEAP (LEnvatinib And Pembrolizumab) clinical program in various tumor types across more than multiple clinical trials.

Exelixis Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, August 1, 2023
General Health, Public Relations, Investor Relations, Health, Communications, Oncology, Table, Prostate cancer, Takeda Pharmaceutical Company, Clinical trial, EXEL, Cancer, GAAP, Research, Patient, Ipilimumab, Collaboration, Survival analysis, Total, Nivolumab, Renal cell carcinoma, Pharmaceutical industry, Reinsurance, Insurance, Exelixis

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the second quarter of 2023 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones.

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the second quarter of 2023 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones.
  • “In the second quarter of 2023, the Exelixis team continued to make steady progress both on our commercial business and our rapidly advancing pipeline,” said Michael M. Morrissey, Ph.D., President and Chief Executive Officer, Exelixis.
  • Exelixis believes that the presentation of these non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors.
  • Exelixis is maintaining the previously provided financial guidance for fiscal year 2023:

RS21's SPAICE Resiliency Tool Accepted into the U.S. Department of Defense Tradewind Solutions Marketplace

Retrieved on: 
Tuesday, July 18, 2023
Hyperspace, RS21, TTF, Failure, Marketplace, STP, SBIR, United States Department of Defense, Intelligence, Research, United States Air Force, Ship, Organization, Starcom: The U.S. Space Force, Machine learning, U.S. Department of Defense Strategy for Operating in Cyberspace, Small Business Innovation Research, Anomaly, Ecosystem, AI, Survival analysis, Telemetry, Data science, Aircraft, Communications satellite

ALBUQUERQUE, N.M., July 18, 2023 /PRNewswire-PRWeb/ -- RS21, a data science company and Inc. 5000 fastest-growing company three years in a row, announced that its AI-powered SPAICE resiliency tool for predictive satellite failure and diagnostics has been accepted into the Tradewind Solutions Marketplace (Marketplace). The Marketplace enables the Department of Defense (DoD) to procure technologies and services non-competitively or sole source.

Key Points: 
  • ALBUQUERQUE, N.M., July 18, 2023 /PRNewswire-PRWeb/ -- RS21, a data science company and Inc. 5000 fastest-growing company three years in a row, announced that its AI-powered SPAICE resiliency tool for predictive satellite failure and diagnostics has been accepted into the Tradewind Solutions Marketplace (Marketplace).
  • The Marketplace enables the Department of Defense (DoD) to procure technologies and services non-competitively or sole source.
  • "Now the DoD can procure our SPAICE resiliency tool without having to go through a lengthy, competitive procurement process."
  • The Tradewind Solutions Marketplace is the DoD's digital environment of post-competition, readily awardable, technology solution pitch videos.